WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Cartesian Therapeutics revenue was $34.17M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $1.1M, down 244.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RNAC annual revenue was $38.9M, with 49.6% growth year-over-year.

RNAC past revenue growth

How has RNAC's revenue growth performed historically?

Company
31.91%
Industry
1,361.15%
Market
34.96%
RNAC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RNAC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RNAC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RNAC revenue history

Current Revenue
$34.2M
Current Earnings
-$42.5M
Current Profit Margin
-124.4%

Be the first to know when RNAC announces revenue.

RNAC Revenue History By Year

RNAC Yearly RevenueRNAC RevenueRNAC ChangeRNAC Revenue Growth
2024-12-31$38.91M$12.91M+49.64%
2023-12-31$26.00M-$84.77M-76.53%
2022-12-31$110.78M$25.70M+30.21%
2021-12-31$85.08M$68.48M+412.60%
2020-12-31$16.60M$9.92M+148.57%
2019-12-31$6.68M$5.77M+639.42%
2018-12-31$903.00k$696.00k+336.23%
2017-12-31$207.00k-$7.88M-97.44%
2016-12-31$8.08M$2.07M+34.47%
2015-12-31$6.01M$2.97M+97.73%
2014-12-31$3.04MN/AN/A

1 of 1

Cartesian Therapeutics Revenue FAQ

What was RNAC's revenue last quarter?

On Invalid Date, Cartesian Therapeutics (NASDAQ: RNAC) reported Q1 2025 revenue of $1.10 million up 81.16% year over year. In the same quarter last year, Cartesian Therapeutics's revenue was $5.84 million.

What was Cartesian Therapeutics's revenue in 2024?

Cartesian Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $38.91 million, a 49.64% increase year over year.

How much does Cartesian Therapeutics make in a day?

Based on Cartesian Therapeutics annual revenue for the past five years, RNAC makes an average of $151,982.47 per day.

What was Cartesian Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Cartesian Therapeutics's revenue has grown 31.91% year over year. This is 1,329.23 percentage points lower than the US Biotechnology industry revenue growth rate of 1,361.15%. Cartesian Therapeutics's revenue in the past year totaled $34.17 million.

How much does Cartesian Therapeutics make in a year?

Cartesian Therapeutics's revenue by year for the past five years is:
  • Cartesian Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $38.91 million, a 49.64% increase year over year.
  • Cartesian Therapeutics's annual revenue for Dec 31, 2023 was $26.00 million, a 76.53% decrease from 2022.
  • Cartesian Therapeutics's annual revenue for 2022 was $110.78 million, a 30.21% increase from 2021.
  • Cartesian Therapeutics's annual revenue for 2021 was $85.08 million, a 412.6% increase from 2020.
  • Cartesian Therapeutics's annual revenue for 2020 was $16.60 million, a 148.57% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.